GSK strengthens emerging markets portfolio with acquisition in Egypt
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlineis to buy Bristol-Myers Squibb's mature products business in Egypt for $210 million in a deal that will see GSK become the leading pharmaceutical company in the country, with a market share of around 9%.